Insulet (NASDAQ:PODD – Get Free Report) had its target price lowered by equities researchers at Piper Sandler from $325.00 to $250.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. Piper Sandler’s target price indicates a potential upside of 53.77% from the company’s current price.
Several other research analysts have also issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Insulet from $375.00 to $330.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 9th. Jefferies Financial Group upgraded shares of Insulet from a “hold” rating to a “buy” rating and decreased their price target for the stock from $260.00 to $240.00 in a research report on Monday, October 2nd. Citigroup upgraded shares of Insulet from a “neutral” rating to a “buy” rating and decreased their price target for the stock from $273.00 to $265.00 in a research report on Monday, August 21st. Robert W. Baird lowered shares of Insulet from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $320.00 to $219.00 in a research report on Monday, August 21st. Finally, TD Cowen decreased their price target on shares of Insulet from $350.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 9th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $254.80.
Insulet Price Performance
Insulet (NASDAQ:PODD – Get Free Report) last posted its quarterly earnings results on Tuesday, August 8th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.14. The firm had revenue of $396.50 million for the quarter, compared to analyst estimates of $383.97 million. Insulet had a net margin of 4.29% and a return on equity of 22.42%. As a group, equities research analysts forecast that Insulet will post 1.65 EPS for the current fiscal year.
Insider Buying and Selling at Insulet
In related news, CEO James Hollingshead bought 5,550 shares of the firm’s stock in a transaction on Monday, August 28th. The stock was bought at an average price of $181.41 per share, with a total value of $1,006,825.50. Following the purchase, the chief executive officer now directly owns 34,177 shares of the company’s stock, valued at approximately $6,200,049.57. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.90% of the company’s stock.
Institutional Investors Weigh In On Insulet
Institutional investors and hedge funds have recently modified their holdings of the business. American National Bank acquired a new stake in shares of Insulet in the 1st quarter valued at $28,000. Allworth Financial LP lifted its stake in shares of Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at $31,000. First Manhattan Co. acquired a new stake in shares of Insulet in the 4th quarter valued at $35,000. Finally, Lindbrook Capital LLC lifted its stake in shares of Insulet by 78.1% in the 1st quarter. Lindbrook Capital LLC now owns 114 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 50 shares during the last quarter.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
- Five stocks we like better than Insulet
- How to Start Investing in Real Estate
- MarketBeat Week in Review – 10/30 – 11/3
- Business Services Stocks Investing
- Shocking uranium play that hedge funds kept hidden
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- Dependable dividends: Why utility stocks are on fire
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.